AYTU
AYTU BIOPHARMA, INC
Key Financials
Gross Profit
$45.8M
↓ 16.0%
Operating Income
$-7827000
↓ 49.0%
Revenue
$66.4M
↓ 18.0%
Net Income
$-13562000
↑ 14.4%
Total Liabilities
$97.1M
↑ 6.1%
EPS (Diluted)
$-5.11
↓ 36.3%
Shareholders' Equity
$19.0M
↓ 31.6%
Total Assets
$124.2M
↑ 5.2%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 4/2/2026 | View on SEC |
| SCHEDULE 13G/A | 2/17/2026 | View on SEC |
| SCHEDULE 13G/A | 2/13/2026 | View on SEC |
| 10-Q | 2/3/2026 | View on SEC |
| 8-K | 2/3/2026 | View on SEC |
| 8-K | 1/20/2026 | View on SEC |
| 8-K | 12/10/2025 | View on SEC |
| SCHEDULE 13G/A | 11/14/2025 | View on SEC |
| 10-Q | 11/13/2025 | View on SEC |
| 8-K | 11/13/2025 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | AYTU |
| Company Name | AYTU BIOPHARMA, INC |
| CIK | 1385818 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 0630 |
| State of Incorporation | DE |
| Phone | (720) 437-6580 |